Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis
Autor: | Yekaterina Butylkova, Martha Skup, Vishvas Garg, J. Kalabic, Alexandra G Ellis, Erin Murray |
---|---|
Rok vydání: | 2018 |
Předmět: |
musculoskeletal diseases
Oncology medicine.medical_specialty Network Meta-Analysis Antibodies Monoclonal Humanized Drug Administration Schedule Arthritis Rheumatoid 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Internal medicine medicine Adalimumab Humans 030212 general & internal medicine skin and connective tissue diseases 030203 arthritis & rheumatology Biological Products business.industry Tumor Necrosis Factor-alpha Health Policy Abatacept Antibodies Monoclonal Bayes Theorem medicine.disease Golimumab Methotrexate Treatment Outcome chemistry Rheumatoid arthritis Meta-analysis Antirheumatic Agents Disease Progression Rituximab Drug Therapy Combination Female business medicine.drug |
Zdroj: | Journal of comparative effectiveness research. 7(10) |
ISSN: | 2042-6313 |
Popis: | Aim: To evaluate the comparative effectiveness of biologics in inhibiting radiographic progression among rheumatoid arthritis (RA) patients. Materials & methods: Bayesian network meta-analysis of published trials investigating the USA FDA approved biologics treatment in RA patients, using methotrexate (MTX) as the reference comparator. Results: Nine trials met the inclusion criteria for base case analysis. Compared with MTX, most biologics (except golimumab) + MTX had significantly lower rates of radiographic progression at 1 year. Mean difference in radiographic progression rates between MTX monotherapy and biologics + MTX was highest for adalimumab + MTX (-3.8) and lowest for tocilizumab + MTX (-0.7). Inhibition of radiographic progression was sustained. Conclusion: Biologics inhibit radiographic progression in patients with RA at 1 year; however, published evidence beyond 1 year is limited. |
Databáze: | OpenAIRE |
Externí odkaz: |